source
- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…BioSpace · 6d ago↗ source
- Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67Michael Ehlers left his CEO role at Ascidian Therapeutics, the exon editing company he co-founded, to run R&D at the AI biotech Formation Bio. It’s not often that biotech executives leave ...Endpoints · 6d ago↗ source
- Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitisSanofi has decided to stop working on a drug for eczema it had hoped would be a successor to its immunological megablockbuster Dupixent. The French pharma said that it won’t seek ...